93 related articles for article (PubMed ID: 7214295)
1. A phase I-II study of maytansine utilizing a weekly schedule.
Franklin R; Samson MK; Fraile RJ; Abu-Zahra H; O'Bryan R; Baker LH
Cancer; 1980 Sep; 46(5):1104-8. PubMed ID: 7214295
[TBL] [Abstract][Full Text] [Related]
2. A therapeutic trial of maytansine.
Blum RH; Wittenberg BK; Canellos GP; Mayer RJ; Skarin AT; Henderson IC; Parker LM; Frei E
Cancer Clin Trials; 1978; 1(2):113-7. PubMed ID: 757139
[TBL] [Abstract][Full Text] [Related]
3. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.
Eagan RT; Ingle JN; Rubin J; Frytak S; Moertel CG
J Natl Cancer Inst; 1978 Jan; 60(1):93-6. PubMed ID: 628025
[TBL] [Abstract][Full Text] [Related]
4. Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Blum RH; Kahlert T
Cancer Treat Rep; 1978 Mar; 62(3):435-8. PubMed ID: 348312
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of maytansine using a 3-day schedule.
Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Conroy J; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):427-30. PubMed ID: 6869315
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
Chahinian AP; Nogeire C; Ohnuma T; Greenberg ML; Sivak M; Jaffrey IS; Holland JF
Cancer Treat Rep; 1979; 63(11-12):1953-60. PubMed ID: 526928
[No Abstract] [Full Text] [Related]
8. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Neidhart JA; Laufman LR; Vaughn C; McCracken JD
Cancer Treat Rep; 1980; 64(4-5):675-7. PubMed ID: 7427953
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical trials of maytansine, an antitumor plant alkaloid.
Chabner BA; Levine AS; Johnson BL; Young RC
Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.
Ravry MJ; Omura GA; Birch R
Am J Clin Oncol; 1985 Apr; 8(2):148-50. PubMed ID: 3834790
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
13. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
15. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
[TBL] [Abstract][Full Text] [Related]
16. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of maytansine in patients with advanced head and neck cancer.
Creagan ET; Fleming TR; Edmonson JH; Ingle JN
Cancer Treat Rep; 1979; 63(11-12):2061-2. PubMed ID: 526939
[No Abstract] [Full Text] [Related]
18. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
19. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
